GET THE APP

In vitro antityrosinase activity of cosmetic creams | 6583
Journal of Clinical & Experimental Dermatology Research

Journal of Clinical & Experimental Dermatology Research
Open Access

ISSN: 2155-9554

+44 1478 350008

In vitro antityrosinase activity of cosmetic creams


7th European Dermatology Congress

June 13-14, 2016 Alicante, Spain

Evgeniya Ranneva, Rodrigo Arroyo, Pierre-Antoine Deglesne and Philippe Deprez

Skin Tech Pharma Group, Spain

Posters & Accepted Abstracts: Clin Exp Dermatol Res

Abstract :

Tyrosinase is a well known key enzyme in melanin biosynthesis. Indeed, it catalyzes two distinct sequential reactions in melanin biosynthesis: The hydroxylation of tyrosine to DOPA followed by the oxidation of DOPA to dopaquinone. Researchers have been looking for new tyrosinase inhibitors as potential depigmenting agent and Kojic acid is well known as one of the safest and most efficient tyrosinase inhibitors. In the present study, we evaluate the results of two cosmetic products in comparison with Kojic acid 1%. One of them contains Kojic acid (1%) associated with Arbutin (0.1%), Glycyrrhiza glabra extract, Morus alba extract, Aspergillus ferment (Blending Bleaching Cream, Skin Tech) and the other does not contain Kojic acid but Arbutin (1%), Nicotinamide Adenine Dinucleotide, Vit C, Glycyrrhiza glabra extract, Morus alba extract, Aspergillus ferment (Aclaranse�?®, Aesthetic Dermal). Both products showed inhibitory effects against mushroom tyrosinase with Aclaranse�?® and Blending Bleaching Cream exhibiting an IC50 values of 3.36 �?¼g per ml and 5.68 �?¼g per mL respectively, compared to Kojic acid (IC50 value of 12.04 �?¼g per ml). The result of inhibition of tyrosinase activity was measured. These results present the high potential of cosmetic products which combine Kojic/Arbutin acid with other active depigmenting ingredients and demonstrate the efficiency of cosmetic products in the inhibition on the activity of the enzyme tyrosinase in vitro, which confirms skin whitening effect already observed clinically through topical application.

Biography :

Email: drranneva@clinicahera.es

Top
https://www.olimpbase.org/1937/